FDA-approves Pasatru (garetosmab-grts) to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) – Regeneron
Regeneron Pharmaceuticals, Inc. announced the FDA has granted approval for Pasatru (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans… read more.
